Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Kasikara C.,,Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression,2017,Molecular Cancer Research,43,10.1158/1541-7786.MCR-16-0350,United States,Article,Newark,1,Journal,2-s2.0-85019883801
Zhang M.,,"The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients",2016,Scientific Reports,65,10.1038/srep37933,China,Article,Harbin,1,Journal,2-s2.0-85000836785
Muro K.,,"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial",2016,The Lancet Oncology,511,10.1016/S1470-2045(16)00175-3,Japan,Article,Nagoya,0,Journal,2-s2.0-84964779633
Böger C.,,PD-L1 is an independent prognostic predictor in gastric cancer of Western patients,2016,Oncotarget,138,10.18632/oncotarget.8169,Germany,Article,Kiel,1,Journal,2-s2.0-84966552789
Eto S.,,Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection,2016,Gastric Cancer,81,10.1007/s10120-015-0519-7,Japan,Article,Tokushima,1,Journal,2-s2.0-84937959229
Mansfield A.,,Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy,2016,Clinical Pharmacology and Therapeutics,16,10.1002/cpt.360,United States,Article,Rochester,0,Journal,2-s2.0-84988971695
Kim J.,,Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer,2016,Gastric Cancer,133,10.1007/s10120-014-0440-5,South Korea,Article,Seongnam,1,Journal,2-s2.0-84951567226
McLaughlin J.,,Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer,2016,JAMA Oncology,405,10.1001/jamaoncol.2015.3638,United States,Article,New Haven,1,Journal,2-s2.0-85010777933
Lin S.J.,,Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas,2015,Gut,100,10.1136/gutjnl-2014-308252,Singapore,Article,Singapore City,1,Journal,2-s2.0-84947942506
Brahmer J.,,Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer,2015,New England Journal of Medicine,4379,10.1056/NEJMoa1504627,United States,Article,Baltimore,1,Journal,2-s2.0-84936791837
Le D.T.,,PD-1 blockade in tumors with mismatch-repair deficiency,2015,New England Journal of Medicine,3862,10.1056/NEJMoa1500596,United States;United States,Article,Baltimore;Baltimore,0,Journal,2-s2.0-84932628341
Cristescu R.,,Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes,2015,Nature Medicine,650,10.1038/nm.3850,United States,Article,Kenilworth,0,Journal,2-s2.0-84937765053
Abiko K.,,IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer,2015,British Journal of Cancer,267,10.1038/bjc.2015.101,Japan,Article,Kyoto,1,Journal,2-s2.0-84928773222
Tamura T.,,Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer,2015,Anticancer Research,53,,Japan,Article,Osaka,0,Journal,2-s2.0-84942794932
Zhang L.,,Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors,2015,International Journal of Clinical and Experimental Pathology,64,,China,Article,Guangzhou,0,Journal,2-s2.0-85013117853
Kim S.,,Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas,2015,European Journal of Cancer,89,10.1016/j.ejca.2015.08.013,South Korea;South Korea,Article,Seoul;Seoul,0,Journal,2-s2.0-84970978445
Ruffell B.,,Macrophages and therapeutic resistance in cancer,2015,Cancer Cell,487,10.1016/j.ccell.2015.02.015,United States;United States,Review,Portland;Tampa,1,Journal,2-s2.0-84928077532
Borghaei H.,,Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,2015,New England Journal of Medicine,4463,10.1056/NEJMoa1507643,United States,Article,Philadelphia,1,Journal,2-s2.0-84944937210
Ferlay J.,,"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012",2015,International Journal of Cancer,16214,10.1002/ijc.29210,France,Article,Lyon,1,Journal,2-s2.0-84918815964
Herbst R.,,Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients,2014,Nature,2576,10.1038/nature14011,United States,Article,New Haven,0,Journal,2-s2.0-84920956735
Bass A.J.,,Comprehensive molecular characterization of gastric adenocarcinoma,2014,Nature,2469,10.1038/nature13480,United States,Article,Boston,1,Journal,2-s2.0-84907270779
Zhu Y.,,CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models,2014,Cancer Research,465,10.1158/0008-5472.CAN-13-3723,United States,Article,St. Louis,1,Journal,2-s2.0-84907484156
Noy R.,,Tumor-Associated Macrophages: From Mechanisms to Therapy,2014,Immunity,1411,10.1016/j.immuni.2014.06.010,United States,Review,New York,1,Journal,2-s2.0-84904406680
Ries C.H.,,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy,2014,Cancer Cell,565,10.1016/j.ccr.2014.05.016,Germany,Article,Grenzach-Wyhlen,1,Journal,2-s2.0-84902546715
Topalian S.L.,,"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab",2014,Journal of Clinical Oncology,1429,10.1200/JCO.2013.53.0105,United States,Article,Baltimore,0,Journal,2-s2.0-84898973055
Soliman H.,,PD-L1 expression is increased in a subset of basal type breast cancer cells,2014,PLoS ONE,135,10.1371/journal.pone.0088557,United States,Article,Tampa,1,Journal,2-s2.0-84895779425
Hou J.,,Correlation between infiltration of FOXP3<sup>+</sup> regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer,2014,Experimental and Molecular Pathology,91,10.1016/j.yexmp.2014.03.005,China,Article,Guangzhou,0,Journal,2-s2.0-84898658808
Sugihara H.,,Identification of miR-30e* regulation of bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer,2013,PLoS ONE,41,10.1371/journal.pone.0081839,Japan,Article,Kumamoto,1,Journal,2-s2.0-84894265866
Hamid O.,,Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,2013,New England Journal of Medicine,2288,10.1056/NEJMoa1305133,United States,Article,Los Angeles,0,Journal,2-s2.0-84879759020
Chen J.,,Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway,2012,Immunobiology,94,10.1016/j.imbio.2011.10.016,China,Article,Chengdu,0,Journal,2-s2.0-84858007569
Bonde A.,,Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors,2012,BMC Cancer,131,10.1186/1471-2407-12-35,Switzerland,Article,Zurich,1,Journal,2-s2.0-84862823626
Francisco L.,,The PD-1 pathway in tolerance and autoimmunity,2010,Immunological Reviews,1070,10.1111/j.1600-065X.2010.00923.x,United States;United States,Review,Boston;Boston,0,Journal,2-s2.0-77953747963
Qian B.,,Macrophage Diversity Enhances Tumor Progression and Metastasis,2010,Cell,2398,10.1016/j.cell.2010.03.014,United States,Review,New York,1,Journal,2-s2.0-77950950894
Wyckoff J.,,Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors,2007,Cancer Research,677,10.1158/0008-5472.CAN-06-1823,United States,Article,New York,1,Journal,2-s2.0-34047246527
Van Cutsem E.,,Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V25 study group,2006,Journal of Clinical Oncology,1529,10.1200/JCO.2006.06.8429,United States,Article,Houston,0,Journal,2-s2.0-33750949065
Sica A.,,Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy,2006,European Journal of Cancer,922,10.1016/j.ejca.2006.01.003,Italy;Italy,Article,Milan;Rozzano,0,Journal,2-s2.0-33645991795
